GRI Bio, Inc. (GRI): R&D Expense
$6.82M
Year ended 2025-12-31
$4.07M
Trailing 12 months to 2026-06-30
+204.3%
3-year compound annual growth
+13.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.82M | +81.0% | 2026-01-30, From 2025-01-01 |
| 2024-12-31 | $3.77M | +16.6% | 2026-01-30, From 2024-01-01 |
| 2023-12-31 | $3.23M | n/m | 2025-03-14, From 2023-01-01 |
| 2022-12-31 | $242.0K | -95.3% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $5.19M | +39.9% | 2023-02-24, From 2021-01-01 |
| 2020-12-31 | $3.71M | n/a | 2022-02-14, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| GRI Bio, Inc. (GRI) | 2025-12-31 | $6.82M | +81.0% |
| CNS Pharmaceuticals, Inc. (CNSP) | 2025-12-31 | $9.77M | +5.2% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $3.65M | -3.1% |
| Nanoviricides, Inc. (NNVC) | 2025-06-30 | $5.55M | +2.1% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $3.07M | -6.8% |
| Lunai Bioworks Inc. (LNAI) | 2025-06-30 | $537.4K | -80.2% |
| ProMIS Neurosciences Inc. (PMN) | 2025-12-31 | $33.38M | +213.8% |
| Soligenix, Inc. (SNGX) | 2025-12-31 | $7.49M | +43.3% |
| GT Biopharma, Inc. (GTBP) | 2025-12-31 | $3.47M | -40.1% |
Compare GRI, CNSP, IGC, NNVC side by side · Screen every company in Pharmaceutical Preparations ↗